Innovative Fusion Superkine and Focused Ultrasound Offer New Hope for Glioblastoma Treatment
Innovative fusion superkine combined with focused ultrasound offers a promising noninvasive therapy for glioblastoma, targeting tumor cells and boosting immune response through advanced delivery techniques.
Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a groundbreaking approach to combat glioblastoma (GBM), one of the most aggressive and deadly brain cancers with no current cure. This innovative strategy combines a novel fusion superkine (FSK), which includes dual therapeutic cytokines, with advanced focused ultrasound technology to deliver the treatment safely across the blood-brain barrier (BBB). The FSK integrates two potent molecules: a next-generation IL-24S (superkine) that induces tumor cell death, and IL-15, which activates important immune cells, enhancing the immune response against cancer cells. In preclinical studies involving glioblastoma models, this combination has demonstrated superior tumor regression and increased survival rates compared to individual cytokines, inspiring hope for more effective treatments.
The delivery method involves creating an adenovirus vector expressing the FSK, which is then transported into the brain using focused ultrasound and microbubbles (FUS-DMB). This technique temporarily and safely opens the BBB, allowing the therapeutic virus to reach tumor sites without invasive surgery—a significant advancement in brain cancer therapy. The researchers aim to expand this approach into clinical trials by 2026, with the goal of providing a noninvasive option for treating primary and secondary brain tumors.
This research marks a significant milestone in immunotherapy and virotherapy fields, addressing the challenges of drug delivery and immune suppression typical of GBM. Experts believe this technology could revolutionize how brain tumors are treated by not only destroying existing tumors but also fostering a long-lasting immune response to prevent recurrence. As the team continues to refine their methods, future studies will explore the potential applications across various tumor types, aiming to ultimately improve patient outcomes worldwide.
Source: https://medicalxpress.com/news/2025-06-fusion-superkine-focused-ultrasound-enable.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding Astigmatism: Causes, Symptoms, and Treatment Options
Discover the causes, symptoms, and effective treatment options for astigmatism, a common refractive error affecting vision clarity worldwide.
Promising Results for HER3-Targeted Antibody-Drug Conjugate in Treatment-Resistant Solid Tumors
Early clinical trial results show that the HER3-targeted antibody-drug conjugate DB-1310 offers hope for patients with resistant advanced solid tumors, including EGFR-mutant non-small cell lung cancer, by extending survival and maintaining manageable side effects.
Persistent Risks of Death and Complications from Broken Heart Syndrome (2016-2020)
Recent studies reveal that the risk of death and major complications from broken heart syndrome remained high in the U.S. from 2016 to 2020, highlighting critical needs for improved diagnosis and management.
New Insights into How Biological and Social Factors Contribute to Health Differences Between Men and Women
A new international study uncovers the biological and social factors contributing to health disparities between men and women, emphasizing the importance of broader health determinants beyond genetics for personalized medicine.